MST Financial is managing the raise and has split it into two tranches. Shares were placed in a trading halt on Thursday.

This week’s ASX Bulls N’ Bears Runner of the Week is… Bio-Gene Technology. The company’s shares leapt after revealing it ...

Alterity Therapeutics (NASDAQ: ATHE) shares moved up at warp-speed Thursday, on announcing positive topline results from the ATH434-201 randomized, double-blind, placebo-controlled Phase 2 clinical ...

Alterity Therapeutics shares are moving higher on Thursday after the company reported positive topline results from its Phase 2 clinical trial of ATH434 in early-stage multiple system atrophy.

Shares of Alterity Therapeutics soared 108% premarket Thursday, surging toward levels last seen in September 2022, with trading volume nearly 75 times the daily average. The clinical-stage biotech ...

European shares were higher today. The eurozone's STOXX 600 rose 0.6%, Germany's DAX 40 gained 0.2% and France's CAC 40 ...

Alterity Therapeutics (ATHE) announced topline results from the ATH434-201 randomized, double-blind, placebo-controlled Phase 2 clinical trial ...

Clinically Meaningful Benefit Observed at Both ATH434 Doses Studied – – Achieved Statistical Significance with Up to 48% Slowing of Clinical Progression on UMSARS Rating Scale – – Key MRI Biomarker ...

Alterity Therapeutics (ATHE) stock jumps as its lead asset, ATH434, shows promise in slowing clinical progression in multiple ...

Alterity Therapeutics (ASX: ATH) has announced positive topline results from a Phase 2 clinical trial of lead candidate ...

Stocks including Appen, Articore and Mineral Resources all dipped following December quarter reports on Thursday.